Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic Clinical Trial

Official title:

A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01471964
• Other study ID #: OER-TH-036
• Secondary ID: NCI-2011-03306
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: October 20, 2011
• Est. completion date: April 10, 2018

Study information

• Verified date: May 2018
• Source: Fox Chase Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Description:

PRIMARY OBJECTIVES:

I. Safety and tolerability of the combination treatment. (Phase I) II. Maximum tolerated dose (MTD) of MLN8237 (alisertib) when given in combination with standard dose erlotinib (erlotinib hydrochloride). (Phase I) III. Progression free survival. (Phase II)

SECONDARY OBJECTIVES:

I. Pharmacokinetic (PK) parameters of erlotinib and MLN8237, including, but not limited to maximum concentration of drug (Cmax), time of occurrence for maximum drug concentration (Tmax), and area under the curve from time zero to the last measurable concentration(AUC0-t last).

II. Overall response rate (ORR), duration of response (DOR), time to progression (TTP), and overall survival (OS). (Phase II) III. Adverse events (AEs), serious adverse events (SAEs), assessments of clinical laboratory values. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of alisertib followed by a phase II study.

Patients receive alisertib orally (PO) twice daily (BID) on days 1-7 and erlotinib hydrochloride PO once daily (QD) on days 1-21. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: April 10, 2018
• Est. primary completion date: February 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with cytologically or histologically confirmed recurrent locally advanced or metastatic NSCLC have received at least one prior recognized systemic therapy for therapy for advanced disease, (recognized therapy must include a platinum doublet unless contraindicated due to organ dysfunction)

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

• Measurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion

• Absolute neutrophil count (ANC) >= 1500/mm^3

• Platelets >= 100,000/mm^3

• Hemoglobin (Hgb) >= 9g/dL

• Total bilirubin =< upper limit of normal (ULN)

• Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 1.5 x ULN; AST and/or ALT may be up to 5 X ULN if with known liver mets

• Adequate renal function as defined by: calculated creatinine clearance must be at least 40 mL/minute (Cockcroft-Gault)

• Serious, active infections must be controlled; patients may be enrolled while still on antibiotics as long as clinical signs of active infection are absent

• Previous radiation allowed provided the patient has recovered from the acute and chronic side effects to =< grade 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events v. 4.0 [CTCAE v 4.0])

• Availability of archival diagnostic tissue (paraffin tissue block of resected tumor, core biopsy, fine needle aspirate cell block, or if block cannot be submitted 20-25 [5 micron] unstained slides cut from a block representative of tumor, is required)

• Able and willing to sign an informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization

• Able and willing to swallow and absorb orally administered medications and maintain a fast as required before and after MLN8237 administration

• Women of childbearing potential (WOCBP) and men who are sexually active, even if surgically sterilized, with WOCBP must agree to use effective methods of contraception during active treatment, for the duration of the study, and for 3 months after the completion of the study

Exclusion Criteria

• Prior treatment with an investigational or marketed inhibitor of the epidermal growth factor receptor (EGFR) pathway or an Aurora Kinase inhibitor

• Patients with mutations in the EGFR gene; the mutational status of all patients will be determined prior to study entry

• Prior malignancy within the past 3 years other than complete resection of basal or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy

• Prior systemic therapy within 14 days of initiating protocol treatment

• Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%; (ongoing small field radiation therapy for palliation only is allowed)

• Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and during the study; anticonvulsants at stable doses are allowed

• Treatment with Proton Pump Inhibitor (PPI); patients on PPI therapy prior to enrollment must stop using the PPI for at least 4 days prior to the first dose of MLN8237

• Known central nervous system (CNS) disease, except for treated brain metastasis; treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period; anticonvulsants (stable doses) are allowed; treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or equivalent) or a combination as deemed appropriate by the treating physician; patients with CNS metastases treated by neurosurgical resection or brain biopsy performed < 4 weeks prior to Day 1 will be excluded

• Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly preclude use of MLN8237 or erlotinib

• Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study

• Unstable angina

• New York Heart Association (NYHA) Grade III or greater congestive heart failure

• History of myocardial infarction within 6 months of enrollment

• Abnormal electrocardiogram (EKG): severe uncontrolled ventricular arrhythmias, or evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any EKG abnormality at screening has to be documented by the investigator as not medically relevant

• Pregnant (positive serum pregnancy test) or breast feeding

• History of any disease that could lead to impaired absorption of drugs

• Known hypersensitivity to any component of the trial agents

• Inability to comply with study and/or follow-up procedures

• Prior allogeneic bone marrow or organ transplantation

• Patient has >= grade 2 (CTCAE v 4.0) peripheral neuropathy within 14 days before enrollment

• Known history of uncontrolled sleep apnea syndrome and other conditions according to enrolling investigator that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen therapy; or requirement of recurrent thoracentesis to manage pleural effusions

• Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer Metastatic
• Non-small Cell Lung Cancer Recurrent

Intervention

Drug:
• MLN8237 and Erlotinib
Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days

Locations

Country	Name	City	State
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Fox Chase Cancer Center	Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of the combination treatment (Phase I)	Toxicity will be evaluated according to the NCI CTCAE, version 4.0.	Participants will be followed for the duration of treatment (up to 2 years) through 30 days of completion of treatment
Primary	MTD of alisertib when given in combination with standard dose erlotinib hydrochloride (Phase I)	MTD is the highest dose tried for which there were either 0 or at most 1 dose-limiting toxicity (DLT) in 6 patients. Any dose that leads to 2 DLTs will be considered too toxic and no additional patients will be treated at that level. Although DLTs may occur at any point during treatment, only DLTs occurring during course 1 of treatment during the Phase 1 portion of this study will necessarily influence decisions regarding dose escalation, expansion of a dose level, or evaluation of intermediate dose levels.	Participants will be followed for the duration of treatment (up to 2 years)
Primary	PFS (Phase II)	PFS and OS will be treated by the method of Kaplan and Meier. The Phase II component will follow a two stage design that allows for early termination of the study if the primary end point of PFS is not met. The phase II part will use an early stopping design 36 that evaluates patients at 9 weeks and again at 18 weeks. Patients still progression free at 9 weeks will remain on study until progression or the end of their follow up period.	Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first
Secondary	PK parameters of erlotinib hydrochloride and alisertib, including, but not limited to Cmax, Tmax, and AUC 0-tlast		Day 7 and day 21 (optional) of course 1
Secondary	ORR (Phase II)	RECIST v1.1 criteria will be used for objective tumor response assessment. Assessments will be performed after every three cycles of treatments (every 9 weeks). Once protocol treatment has been completed subjects will be assessed every three months or sooner as indicated and judged by treating physicians.	Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first
Secondary	DOR (Phase II)	The duration of overall response is measured from the time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).	Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first
Secondary	TTP (Phase II)		Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first
Secondary	OS (Phase II)	PFS and OS will be treated by the method of Kaplan and Meier.	Participants will be followed for the duration of treatment (up to 2 years) until the date of first documented progression or date of death for any cause, whichever came first
Secondary	AEs, SAEs, and assessments of clinical laboratory values (Phase II)	AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure regardless of whether it is considered related to the medical treatment or procedure. Attributable AE, with CTCAE v4 grading should be monitored and recorded until resolved to =< grade I or determined to be irreversible.	Participants will be followed for the duration of treatment (up to 2 years) through 30 days of completion of treatment